Asunto(s)
Trasplante de Células Madre Hematopoyéticas/efectos adversos , Enfermedad Veno-Oclusiva Hepática/tratamiento farmacológico , Trombomodulina/uso terapéutico , Adolescente , Adulto , Niño , Preescolar , Femenino , Neoplasias Hematológicas/complicaciones , Neoplasias Hematológicas/terapia , Enfermedad Veno-Oclusiva Hepática/etiología , Humanos , Lactante , Masculino , Proteínas Recombinantes/uso terapéutico , Resultado del Tratamiento , Adulto JovenRESUMEN
Intravenous immunoglobulin (IVIG) produces a rapid and prolonged increase in the platelet counts of children with immune thrombocytopenia (ITP). The mechanism of IVIG efficacy in a murine model of ITP has been reported to operate through an IVIG-mediated increase in the expression of the inhibitory Fc receptor FcγRIIB(CD32B) on splenic macrophages. This investigation examined whether IVIG administration results in a similar increase in FcγRIIB expression on peripheral blood CD14(+) monocytes in 20 children with ITP. FcγRIIB expression on peripheral blood monocytes was measured by flow cytometry in ITP patients, before and after IVIG therapy, as well as in control subjects. Peripheral blood monocytes were labelled with fluorescent-specific antibodies. There were no significant differences in the absolute number of [corrected] CD14(+) CD32B(+) monocytes, and [corrected] the percentages of CD14(+) CD32B(+) cells in mononuclear cells or monocytes. [corrected]. We suggest that IVIG does not increase FcγRIIB expression in peripheral blood monocytes in children with ITP.
